Sildenafil Citrate
Product Images NDC 50436-0295

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 50436-0295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360295)

Sildenafil Citrate 20 mg unit dose pouch label from Unit Dose Services with NDC 50436-0295. The label includes dosage strength, formulation details, storage instructions, and manufacturer information. It also features handling warnings, a barcode, and a QR code for product verification.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

A survival analysis Kaplan-Meier curve showing estimated cumulative mortality rates over five years for three dose groups labeled High Dose, Medium Dose, and Low Dose. The x-axis represents time in years, while the y-axis shows estimated cumulative mortality rate as a percentage. Number at risk values are displayed above the x-axis for each dose group at different time points.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

A forest plot chart showing fold changes and 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) of sildenafil when coadministered with various interacting drugs, including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir. Recommendations on dose adjustment are indicated, mostly stating 'No dose adjustment' except 'Coadministration not recommended' for Ritonavir.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

A chart depicting the fold change and 90% confidence interval in pharmacokinetic parameters (AUC, Cmax, INR, BT) of various interacting drugs when co-administered with sildenafil. The horizontal axis shows change relative to the interacting drug alone, centered at 1. Recommendations for dose adjustment are indicated, mostly showing no dose adjustment needed except for ritonavir, where coadministration is not recommended.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

A line plot showing the change from baseline in meters over weeks 4, 8, and 12 for a study on Sildenafil Citrate. The x-axis represents the week of study, and the y-axis represents change from baseline in meters. Four groups are compared: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, each with error bars indicating variability.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

A forest plot chart comparing sildenafil 20 mg three times daily to placebo, showing placebo-corrected changes in 6-minute walk distance (meters) across various patient subgroups including baseline walk distance, etiology of pulmonary arterial hypertension, functional class, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index. Each subgroup displays sample sizes and confidence intervals of treatment effect.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

A line graph depicting the percentage of patients without a clinically worsening event over time (days from randomization) comparing Sildenafil and Placebo groups. The vertical axis shows percentage without events, and the horizontal axis shows days up to 112. Sildenafil group maintains a higher percentage without worsening compared to Placebo.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

A line plot showing mean change from baseline in meters over a 12-week study for Sildenafil administered at 1 mg, 5 mg, and 20 mg three times daily (TID). The plot includes error bars representing standard error at weeks 4, 8, and 12 for each dosage group.*

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

Chemical structure diagram of the active ingredient Sildenafil Citrate, showing molecular bonds and groups including the sulfonamide and piperazine rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.